Market Place
Sourcing Support
Sumitovant Biopharma Acquires Myovant Sciences in $1.7B Deal
10 Mar 2023 //
CONTRACT PHARMA
Neochromosome and Sumitovant Announce Collaboration for Protein Drug Discovery
19 Jan 2023 //
BUSINESSWIRE
Sumitovant subsidiaries Enzyvant and Altavant merge into combined company
06 Dec 2022 //
ENDPTS
Weeks after Rejecting First Offer, Myovant Agrees to Acquisition by Sumitovant
25 Oct 2022 //
BIOSPACE
Myovant`s Board Confirms Sumitovant & Sumitomo to Acquire Remaining Shares
02 Oct 2022 //
GLOBENEWSWIRE
The Impact of Urinary Incontinence Related to Overactive Bladder
13 Jul 2022 //
BUSINESSWIRE
Urovant Sciences Presents New Data from EMPOWUR Study at AUA
15 May 2022 //
BUSINESSWIRE
Urovant Shows Positive Topline Results of Phase 2a Trial of URO-902
07 Mar 2022 //
BUSINESSWIRE
Sumitomo Dainippon, Sumitovant Biopharma Initiate Phase 1 Study
10 Feb 2022 //
PRESS RELEASE
PharmStars digital health accelerator wraps first `PharmU` startup class
11 Jan 2022 //
ENDPTS
Urovant to publish in Advances in Therapy of Improvement by GEMTESA in OAB
20 Dec 2021 //
BUSINESSWIRE
Urovant Makes Appointments to Drive Future Growth & Geographic Expansion
18 Oct 2021 //
BUSINESSWIRE
Sumitovant Has a Strong Fourth Quarter with Significant Clinical Development
26 May 2021 //
PRNEWSWIRE
FDA clears Sumitovant`s Gemtesa for patients with overactive bladder
24 Dec 2020 //
GLOBENEWSWIRE
Urovant gets snapped up by Sumitovant Biopharma
13 Nov 2020 //
FIERCEBIOTECH
Sumitovant and Urovant Sciences Announce Sumitovant`s Urovant
12 Nov 2020 //
BIOSPACE
Sumitovant Announces Priority Review & FDA Acceptance of Myovant Sciences
22 Jun 2020 //
GLOBENEWSWIRE
Sumitovant Announces Urovant Collaboration with Sunovion Pharmaceuticals
19 Jun 2020 //
GLOBE NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.